Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation
AI generated
Nov 14, 2026, 23:32

Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation

Kalyan Roy, Specialist Transfusion Medicine Center at Square Hospitals LTD, shared a post on LinkedIn:

“A new era in anticoagulation? Can we prevent blood clots without increasing bleeding risk?

A significant milestone in cardiovascular medicine!

On November 9, 2026, the US FDA approved Asundexian (SUNHARBO®), developed by Bayer — the first approved drug in a new class of anticoagulants known as Factor XIa inhibitors.

What makes it different?

Unlike conventional anticoagulants that target Factor Xa or thrombin, Asundexian selectively inhibits activated Factor XI (FXIa), an important component of the intrinsic coagulation pathway.

The goal?

To prevent pathological thrombosis while preserving more of the body’s natural haemostatic response.

Oceanic-Stroke: Key clinical findings

A landmark Phase III trial involving 12,327 patients demonstrated:

  • 26 percent lower relative risk of recurrent ischemic stroke.
  • Recurrent ischemic stroke: 6.2 percent with Asundexian versus 8.4 percent with placebo.
  • Major bleeding: 1.9 percent versus 1.7 percent, with no statistically significant difference.
  • Treatment: 50 mg orally once daily, alongside standard antiplatelet therapy.

Important clinical considerations

  • Asundexian reduces stroke risk; it does not eliminate it.
  • Gastrointestinal bleeding remains an important safety consideration.
  • It is not approved as a replacement for conventional anticoagulation in atrial fibrillation.
  • The findings apply to the specific non-cardioembolic stroke prevention population studied.

Why does this matter?

For decades, clinicians have faced a difficult balance between preventing thrombosis and increasing bleeding risk.

Factor XIa inhibition represents a promising approach to achieving more selective antithrombotic protection.

The future of anticoagulation may not simply be about stronger blood thinners — but smarter and more targeted inhibition of coagulation.

A fascinating development for clinicians, haematologists, cardiologists and transfusion medicine specialists!

Key Reference: Sharma M, et al. OCEANIC-STROKE. The New England Journal of Medicine, 2026.”

Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation

Other posts featuring Kalyan Roy on Hemostasis Today.

asundexian Factor XI Gastrointestinal Bleeding Health Hematology Hemostasis Hemostasis News Hemostasis Today Kalyan Roy Medicine
NewsFeed